Unravelling sex-specific BPA toxicokinetics in children using a pediatric PBPK model

Deepika Deepika1, Raju Prasad Sharma1, Marta Schuhmacher1

  • 1Environmental Engineering Laboratory, Departament D' Enginyeria Quimica, Universitat Rovira I Virgili, Av. Països Catalans 26, 43007, Tarragona, Catalonia, Spain.

Environmental Research
|August 22, 2022
PubMed

Insights

This study developed a sex-specific pediatric model to assess Bisphenol A (BPA) exposure, finding children

Area of Science:

  • Environmental Health
  • Toxicology
  • Pharmacokinetics

Background:

  • Bisphenol A (BPA) is a common endocrine disruptor (ED) found in children's products.
  • Postnatal BPA exposure is linked to diseases like diabetes, obesity, and neurodegeneration.
  • Limited understanding exists regarding sex-specific BPA metabolism and internal exposure in children.

Purpose of the Study:

  • To develop a sex-specific pediatric physiologically based pharmacokinetic (PBPK) model for BPA.
  • To compare toxicokinetic differences between sexes using the developed PBPK model.
  • To evaluate BPA exposure levels in children against established tolerable daily intake (TDI).

Main Methods:

  • Validated an existing adult PBPK model and extended it with pediatric sex-specific parameters.
  • Employed both body weight and ontogeny-based scaling approaches for metabolic interpolation.
  • Compared pharmacokinetic attributes using different scaling methods and selected an ontogeny-based sex-specific model.

Main Results:

  • The developed sex-specific pediatric PBPK model successfully estimated BPA exposure in two European cohorts.
  • BPA half-life was found to be similar in boys and girls at equivalent exposure levels.
  • Estimated children's BPA exposure was approximately 1500 times higher than the EFSA's TDI.

Conclusions:

  • The study demonstrates the feasibility of extending adult PBPK models to pediatric, sex-specific applications.
  • The developed model can investigate gender-specific health risks associated with BPA exposure.
  • Urgent attention is needed regarding high BPA exposure levels in children compared to safety limits.

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
77
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
135
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
89
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.0K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
121
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
115